SCIENCE
SCIENCE
Reference. J. Glaucoma. Biology of the Extracellular Matrix: An Overview (2015)
SCIENCE
Establishment of a blood exchange system between old and young mice (Heterochronic parabiosis)
Confirmation of the tissue regeneration in the dermis of the old mice paired with young mice
Analysis Method: Through aptamer-based proteomic analysis enabling to perform ultra-trace level qualitative
and quantitative analysis of protein groups distributed in the blood, specific cells, tissues, and organs in the body
HAPLN1 (Hyaluronan And Proteoglycan Link proteiN1) is an endogenous glycoprotein widely present in the extracellular matrix (ECM) of human and animal blood or tissues that stably binds hyaluronic acid (high molecular polysaccharide) and proteoglycan (complex glycoprotein) stoichiometrically. It exhibits various effects and functions such as moisturizing, viscosity, elasticity, etc. As a mechanical, chemical, and biological defense material against external stimuli, HAPLN1 has a characteristic that decreases with aging.
HaplnScience, Inc. is the first in the world to discover a new function of HAPLN1 that not only rejuvenates aging skin but also promotes regeneration of various human tissues that are deteriorated with age by identifying HAPLN1 as an endogenous protein that rejuvenates the dermis of old mice, through an experimental heterochronic parabiosis study.
When the purified recombinant HAPLN1 was administered to old mice, the epidermal and dermal layer thickness increased, and collagen and hyaluronic acid levels, which were significantly reduced compared to the young mice, were restored. Interestingly, in the established alopecia model using mouse, it was observed hair generation was remarkably promoted in a beta-catenin-dependent manner.
In addition, the administration of recombinant HAPLN1 protein to the knee joint cavity in the osteoarthritis-induced sheep model significantly improved the structure of the joint and normalized the cartilage and joint environment at the same time. Also, the osteoarthritis model of Rat and goat observed similar improvement along with pain relief effects, showing the potential for development as a first-in-class DMOAD (Disease-Modifying Osteoarthritis Drug) candidate.
On the other hand, in the elastase-induced mouse model of chronic obstructive pulmonary disease (COPD), which occurs frequently in the elderly mainly due to smoking and fine dust, when the recombinant HAPLN1 protein was inhaled in the form of an aerosal, the lung tissue that had already been destroyed/damaged by disease induction was restored to an almost normal level and the effect of restoring the damaged lung tissue of COPD patients was confirmed. This showed the possibility of developing a candidate drug for treating COPD that can regenerate damaged lung tissue, which is not yet developed anywhere in the world.
Lastly, when HAPLN1 protein was administered as eye drops to an animal model of dry eye disease, it showed superior efficacy compared to the currently launched dry eye products. In particular, by using dry eye induced rabbit models to compare HAPLN1 with Restasis, a product that is occupying the first place in the market of dry eye treatment, it showed excellent tear film recovery and corneal detachment treatment effects. This showed high potential of hAPLN1 as a new dry eye disease treatment that can solve unmet medical needs as an eye drop that does not cause discomfort such as foreign body sensation and burning sensation when administered.
HaplnScience aims to develop a first-in-class protein drug that can fundamentally treat various refractory chronic diseases caused by aging-related degeneration while clarifying the mechanism of action that explains these new functions of the recombinant HAPLN1.